Syntara Limited Hosts Webinar on Skin Scarring Program Developments

The latest update is out from Pharmaxis Ltd ( (AU:SNT) ).

Syntara Limited announced an investor webinar to discuss advancements in its skin scarring program, featuring CEO Gary Phillips and skin scarring expert Professor Fiona Wood. The company is actively developing its lead candidate SNT-5505 for myelofibrosis and other drug candidates for fibrotic and inflammatory diseases. The webinar aims to engage stakeholders and provide updates on Syntara’s progress, potentially impacting its industry positioning and stakeholder interests.

More about Pharmaxis Ltd

Syntara Limited is a clinical stage drug development company based in Sydney, Australia. It specializes in targeting extracellular matrix dysfunction using amine oxidase chemistry and other technologies to create novel medicines for blood cancers and conditions related to inflammation and fibrosis. The company has developed drug candidates for various diseases, including myelofibrosis, myelodysplastic syndrome, and neurodegenerative diseases like Parkinson’s. Syntara is listed on the Australian Securities Exchange under the code SNT.

YTD Price Performance: -2.50%

Average Trading Volume: 3,269,890

Technical Sentiment Consensus Rating: Sell

Current Market Cap: A$126.6M

For a thorough assessment of SNT stock, go to TipRanks’ Stock Analysis page.